Evotec SE (EVT.F)

9,77 -0,23 (-2,30%) Börsenschluss: 09:49PM CEST

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 5.061

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Mario Polywka DPHIL, Ph.D.	CEO & Chairman of the Management Board & Member of the Supervisory Board	N/A	N/A	1963
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	804k	N/A	1964
Dr. Craig Johnstone Ph.D.	COO & Member of Management Board	712k	N/A	1970
Dr. Matthias Evers Ph.D.	Chief Business Officer & Member of Management Board	636k	N/A	1973
Ms. Laetitia Rouxel	CFO & Member of Management Board	N/A	N/A	1975
Ms. Anja Bosler	Principal Accounting Officer and Senior Vice President of Group Accounting	N/A	N/A	N/A
Mr. Volker Braun	Executive VP and Head of Global Investor Relations & ESG	N/A	N/A	N/A
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/A	N/A	N/A
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	N/A	N/A	N/A
Dr. Ian M. Hunneyball	Senior Vice President of Programme Management & Clinical Operations	116k	N/A	1950

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Corporate Governance

Evotec SEs ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 4, Vorstand: 4, Shareholderrechte: 1, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.